Sodium-glucose cotransporter-2 inhibitors: A treatment option for recurrent vasovagal syndrome?

The increasing prevalence of metabolic disease, along with cardiometabolic multimorbidity remains a leading healthcare challenge, despite advances in biomarker discovery and a broad pharmacological armamentarium [1 –4]. Sodium-glucose cotransporter-2 (SGLT2) inhibitors introduced a paradigm shift in the management of diabetes. They have been shown to lower glycated hemoglobin, fasting and postprandial plasma glucose levels, body weight, and blood pressure, while also offering cardio- and nephroprotection (Fi g.
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Source Type: research